Exact Sciences Corp (EXAS) Misses Q1 Expectations
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 hits record high as rate-hike worries ease
- Oil pares losses after reports Houthis attacked Saudi Aramco refinery
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Burry doubles down on Nebius short after stock surges 34% on earnings
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Home Depot CEO Ted Decker takes medical leave; two executives step in
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Exact Sciences (EXAS) Spec Buy Reiterated at Benchmark; Co. Anything But Revenue and Earnings Story
May 1, 2014 2:57 PM EDTBenchmark maintained a Speculative Buy rating on Exact Sciences (NASDAQ: EXAS) with a price target of $25.00. Comments follow Q1 results.
"Revenues were $0.3 Million and EPS was ($0.23). That being said, Exact Sciences is anything but a revenue and earnings storyat least for now. The company made significant progress on two fronts. The publication of the results of the DEEP-C Study in the New England Journal of Medicine highlighted what the benefits of the... More
